Evidence map›Paper›PMID 39676060›Full record

ArticleChemistry (Weinheim an der Bergstrasse, Germany)2025

Dynamic Combinatorial Chemistry Unveils Nsp10 Inhibitors with Antiviral Potential Against SARS-CoV-2.

Ravindra P Jumde, Gwenaëlle Jézéquel, Margarida Saramago, Nicolas Frank, Sebastian Adam, Marta V Cunha, Chantal D Bader, Antonia P Gunesch, Natalie M Köhler, Sandra Johannsen and 6 more

Abstract read
In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ravindra P JumdeHelmholtz Institute for Pharmaceutical Research Saarland (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus E 8.1, 66123, Saarbrücken, Germany.ORCID https://orcid.org/0000-0002-2674-9605
Gwenaëlle JézéquelHelmholtz Institute for Pharmaceutical Research Saarland (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus E 8.1, 66123, Saarbrücken, Germany.ORCID https://orcid.org/0000-0001-8945-8680
Margarida SaramagoInstituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Avenida da República, 2780-157, Oeiras, Portugal.ORCID https://orcid.org/0000-0003-0458-1036
Nicolas FrankHelmholtz Institute for Pharmaceutical Research Saarland (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus E 8.1, 66123, Saarbrücken, Germany.
Sebastian AdamHelmholtz Institute for Pharmaceutical Research Saarland (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus E 8.1, 66123, Saarbrücken, Germany.ORCID https://orcid.org/0000-0003-3319-6356
Marta V CunhaInstituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Avenida da República, 2780-157, Oeiras, Portugal.ORCID https://orcid.org/0009-0005-3380-5993
Chantal D BaderHelmholtz Institute for Pharmaceutical Research Saarland (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus E 8.1, 66123, Saarbrücken, Germany.ORCID https://orcid.org/0000-0003-3560-7956
Antonia P GuneschInstitute for Experimental Virology, Twincore - Centre for Experimental and Clinical Infection Research, Feodor-Lynen-Str. 7, 30625, Hannover, Germany.ORCID https://orcid.org/0000-0003-2649-7556
Natalie M KöhlerInstitute for Experimental Virology, Twincore - Centre for Experimental and Clinical Infection Research, Feodor-Lynen-Str. 7, 30625, Hannover, Germany.ORCID https://orcid.org/0000-0002-7502-0431
Sandra JohannsenHelmholtz Institute for Pharmaceutical Research Saarland (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus E 8.1, 66123, Saarbrücken, Germany.ORCID https://orcid.org/0000-0003-2306-2071
Spyridon BousisHelmholtz Institute for Pharmaceutical Research Saarland (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus E 8.1, 66123, Saarbrücken, Germany.
Thomas PietschmannInstitute for Experimental Virology, Twincore - Centre for Experimental and Clinical Infection Research, Feodor-Lynen-Str. 7, 30625, Hannover, Germany.ORCID https://orcid.org/0000-0001-6789-4422
Rute G MatosInstituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Avenida da República, 2780-157, Oeiras, Portugal.ORCID https://orcid.org/0000-0002-9788-7562
Rolf MüllerHelmholtz Institute for Pharmaceutical Research Saarland (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus E 8.1, 66123, Saarbrücken, Germany.ORCID https://orcid.org/0000-0002-1042-5665
Cecília M ArraianoInstituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Avenida da República, 2780-157, Oeiras, Portugal.ORCID https://orcid.org/0000-0003-1934-9301
Anna K H HirschHelmholtz Institute for Pharmaceutical Research Saarland (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus E 8.1, 66123, Saarbrücken, Germany.ORCID https://orcid.org/0000-0001-8734-4663

Funding

Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy - EXC 2155 "RESIST" Project ID 390874280FCT - Fundação para a Ciência e a Tecnologia, I.P. CEECIND/02065/2017FCT - Fundação para a Ciência e a Tecnologia, I.P. PTDC/BIA-BQM/28479/2017FCT - Fundação para a Ciência e a Tecnologia, I.P. contract according to DL57/2016 SFRH/BPD/109464/2015FCT - Fundação para a Ciência e a Tecnologia, I.P., through MOSTMICRO-ITQB R&D Unit UIDB/04612/2020, UIDP/04612/2020LS4FUTURE Associated Laboratory LA/P/0087/2020Niedersächsisches Ministerium für Wissenschaft und Kultur (Ministry for Science and Culture of Lower Saxony) grant 14-76103-184 CORONA-13/20
6 · The paper itself

Abstract

The development of antiviral drugs against the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) responsible for the recent Covid-19 pandemic is crucial, as treatment options remain limited and vaccination does not prevent (re)infection. Two relatively underexplored targets of this virus are the 3'-5' exoribonuclease (ExoN) and the 2'-O-methyltransferase (2'-O-MTase), both essential for viral viability. The non-structural proteins Nsp14 and Nsp16 exhibit enzymatic activities for ExoN and 2'-O-MTase, respectively, especially when in complex with their co-factor protein Nsp10. The study focuses on the use of target-directed dynamic combinatorial chemistry (tdDCC) to identify binders of Nsp10, aiming to disturb the protein-protein interactions (PPI) involving Nsp10-Nsp14, as well as Nsp10-Nsp16. We synthesised the hits and evaluated them to assess Nsp10 affinity, ExoN and 2'-O-MTase activities inhibition, and antiviral activity in hCoV-229E and SARS-CoV-2-infected whole-cell settings. This study reports a novel class of ExoN and/or 2'-O-MTase inhibitors exhibiting antiviral activity against coronaviruses.

Indexed as

Antiviral AgentsCOVID-19 Drug TreatmentEnzyme InhibitorsExoribonucleasesSARS-CoV-2Viral Nonstructural ProteinsCombinatorial Chemistry TechniquesCOVID-19HumansMethyltransferasesProtein BindingViral Regulatory and Accessory ProteinsAntiviral AgentsEnzyme InhibitorsExoribonucleasesMethyltransferasesNSP14 protein, SARS-CoV-2NSP16 protein, SARS-CoV-2ORF1ab polyprotein, SARS-CoV-2Viral Nonstructural ProteinsViral Regulatory and Accessory ProteinsNsp10Nsp14Nsp16SARS-CoV-2target-directed dynamic combinatorial chemistry

Identifiers

PMID39676060
PMCPMC11739841

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.